Results 251 to 260 of about 291,142 (306)

Determinants of natural killer cell-mediated antibody dependent cellular cytotoxicity in SARS-CoV-2 antibodies. [PDF]

PLoS Pathog
Depierreux DM, Ruiz F, Lilly M, Guenthoer J, Chohan V, Overbaugh J.   +5 more
europepmc   +1 more source

Coxsackie B1 virus-like particle that lacks VP4 protein demonstrates improved vaccine scalability, stability and immunogenicity. [PDF]

J Biomed Sci
Soppela S, Kyröläinen HM, Levanova A, Nekoua MP, González-Rodríguez M, Lehto H, Ahmad KLL, Guryanov S, Hytönen VP, Laitinen OH, Junttila IS, Hober D, Butcher SJ, Hankaniemi MM.   +13 more
europepmc   +1 more source

Development of canine parvovirus-neutralizing monoclonal antibodies from natural host and their germline gene usage. [PDF]

Appl Microbiol Biotechnol
Liu G, Fu P, Zhang X, Kong F, Peng J, Kang D, Pei Y, Li K, Lu Z.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Broadly Neutralizing Antiviral Antibodies

Annual Review of Immunology, 2013
A fascinating aspect of viral evolution relates to the ability of viruses to escape the adaptive immune response. The widely held view has been that the great variability of viral glycoproteins would be an absolute obstacle to the development of antibody-based therapies or vaccines that could confer broad and long-lasting protection.
Corti D., Lanzavecchia A.
openaire   +2 more sources

Neutralizing Antibodies Against Calcitonin

Hormone and Metabolic Research, 1993
The use of calcitonin (CT) is established as a treatment of Paget's disease of bone and postmenopausal osteoporosis (PMO). Salmon calcitonin (sCT), which differs in 14 of the 32 amino acids from human calcitonin, has found a wider distribution world wide, although antibody formation against sCT has been reported in more than 70% of the patients on ...
A, Grauer, H H, Reinel, R, Ziegler, F, Raue   +3 more
openaire   +2 more sources